BioSpace News Archive

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2022 financial results after market close on Thursday, August 11, 2022.

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 11, 2022 at 4 pm CET (10 am ET) following the announcement of results for the second quarter of 2022.

Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it will present additional Phase 2a data highlighting improved lipid composition and potential cardiovascular benefits of denifanstat in nonalcoholic steatohepatitis (NASH) patients.

Applied DNA Sciences, Inc., (NASDAQ: APDN) (the “Company” or “Applied DNA”), a leader in polymerase chain reaction (“PCR”)-based technologies, today announced the pricing of a public offering of 3,000,000 shares of its common stock.

Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties.

Last year, US Capital Global Securities LLC launched a convertible note offering of up to $30 million for QT Imaging, Inc., an innovative MedTech company that continues to reach new milestones in product development, testing, and clearance.

AnHeart Therapeutics announced it will host an investigator meeting in addition to a e-poster presentation at the World Conference on Lung Cancer in Vienna, Austria at 11:00 am ET on Sunday, Aug. 7, 2022.

Halberd Corporation (OTC Pink: HALB) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd’s research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

Spineology Inc., the longtime leader in ultra-minimally invasive spine surgery, announces another milestone today with the limited launch of OptiLIF® Endo.